630125-84-7

Upstream product

• 350-96-9 2,2,2-trifluoro-N-(4-methylphenyl)acetamide 
• 65934-74-9 3-(trifluoromethyl)-4-methylaniline 

Downstream Products

• 630125-83-6 2,2,2-trifluoro-N-(4-piperidin-1-ylmethyl-3-trifluoromethyl-phenyl)-acetamide 
• 709045-30-7 2,2,2-trifluoro-N-[4-(4-methyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-acetamide 
• 853297-25-3 4-((dimethylamino)methyl)-3-(trifluoromethyl)aniline 
• 694499-26-8 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline 
• 694499-30-4 4-(morpholin-4-ylmethyl)-3-(trifluoro-methyl)aniline 
• 630125-91-6 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine 
• 882408-16-4 4-pyrrolidin-1-ylmethyl-3-trifluoromethyl-phenylamine 
• 853297-41-3 4-(azetidin-1-ylmethyl)-3-trifluoromethyl-aniline 
• 853297-26-4 N-(3-trifluoromethyl-4-((dimethylamino)methyl)phenyl)-2,2,2-trifluoroacetamide 
• 853297-23-1 4-(4-tert-butyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl-amine 
• 853297-19-5 N-[4-(6-methylamino-pyrimidin-4-yloxy)-phenyl]-N'-[4-(4-H-piperazin-1-ylmethyl)-5-trifluoromethyl-phenyl]-urea 
• 1072710-85-0 4-(9-methyl-3.9-diaza-bicyclo[3.3.1]non-3-ylmethyl)-3-trifluoromethyl-phenylamine 
• 859027-12-6 4-(1-methyl-piperidin-4-ylmethyl)-3-trifluoromethyl-phenylamine 
• 859027-09-1 4-(1-methyl-piperidin-4-ylidenemethyl)-3-trifluoromethyl-phenylamine 

Relevant academic research and scientific papers

Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8

Using Sorafenib as a starting point, a series of potent and selective inhibitors of CDK8 was developed. When cocrystallized with CDK8 and cyclin C, these compounds exhibit a Type-II (DMG-out) binding mode.

Syntheses of a triad of Flt3 kinase inhibitors: From bench to pilot plant

We have designed and developed an alternative synthesis for the manufacturing of a triad of Flt3 kinase inhibitors (AST487, ATH686, and AUZ454) to support clinical assessments of patients with Flt3-dependent tumor diseases. The new synthesis is convergent

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives for the manufacture of pharmaceutical compositions for the treatment of RET dependent disorders, especially RET dependent tumor diseases. The invention further relates to novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and their use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease, to pharmaceutical compositions comprising such novel N-[4-pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives and to the use of such novel N-[4-(pyrimidin-4-yloxy)-phenyl]-N’-phenyl-urea derivatives for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as tumour diseases.

ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE

The present invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof - alone or in combination with one or more

DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of diaryl urea derivatives in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising diaryl urea derivatives for the treatment of said diseases, diaryl urea derivatives for use in the treatment of said diseases, novel diaryl urea derivatives, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.